Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “RAF Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT04985604
What this trial is testing

Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

Who this might be right for
MelanomaSolid TumorCRAF Gene Amplification+20 more
Day One Biopharmaceuticals, Inc. 23
Early research (Phase 1)Looking for participantsNCT04913285
What this trial is testing

Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

Who this might be right for
Solid Tumor, AdultNon-small Cell Lung CancerMelanoma
Pierre Fabre Medicament 400
Large-scale testing (Phase 3)Looking for participantsNCT05768178
What this trial is testing

DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

Who this might be right for
Haematological MalignancyMelanomaThyroid Cancer, Papillary+9 more
Cancer Research UK 30
Not applicableStudy completedNCT01720758
What this trial is testing

Assessment of the V600E Mutation in the B-RAF Gene in Chronic Lymphoproliferative Disease

Who this might be right for
Hairy Cell LeukemiaSplenic Marginal Zone Lymphoma
HaEmek Medical Center, Israel 20
Not applicableApproved For MarketingNCT05760586
What this trial is testing

Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma

Who this might be right for
Low-grade Glioma
Day One Biopharmaceuticals, Inc.
Not applicableUnknownNCT03401957
What this trial is testing

The Emergence of RAS Mutations in Metastatic Colorectal Cancer Patients Receiving Cetuximab Treatment

Who this might be right for
Colorectal CancerDrug ResistanceMass Spectrometry+1 more
National Health Research Institutes, Taiwan 120
Testing effectiveness (Phase 2)Looking for participantsNCT05786924
What this trial is testing

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Who this might be right for
Non-small Cell Lung CancerHistiocytic NeoplasmHistiocytosis+29 more
Institut de Recherches Internationales Servier 554
Early research (Phase 1)Ended earlyNCT01400451
What this trial is testing

Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)

Who this might be right for
Melanoma
Bristol-Myers Squibb 18
Very early researchLooking for participantsNCT06610682
What this trial is testing

A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF-altered Glioma

Who this might be right for
BRAF V600E Mutation
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 24
Testing effectiveness (Phase 2)Study completedNCT04620330
What this trial is testing

Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung CancerKRAS Activating Mutation
Verastem, Inc. 90
Early research (Phase 1)Study completedNCT01363232
What this trial is testing

Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients

Who this might be right for
Advanced Solid TumorsSelected Solid Tumors
Array Biopharma, now a wholly owned subsidiary of Pfizer 89
Testing effectiveness (Phase 2)Ended earlyNCT04198818
What this trial is testing

Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors

Who this might be right for
Advanced TumorsMelanomaNon-Small-Cell Lung Cancer+2 more
Haihe Biopharma Co., Ltd. 37
Early research (Phase 1)Study completedNCT01155453
What this trial is testing

Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients

Who this might be right for
Advanced and Selected Solid Tumors
Novartis Pharmaceuticals 113
Early research (Phase 1)Ended earlyNCT06287463
What this trial is testing

Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

Who this might be right for
Advanced Solid TumorRAF MutationRAS Mutation+7 more
Deciphera Pharmaceuticals, LLC 29
Testing effectiveness (Phase 2)UnknownNCT02968303
What this trial is testing

Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy

Who this might be right for
Melanoma, Malignant, of Soft Parts
Radboud University Medical Center 200
Early research (Phase 1)Ended earlyNCT06270082
What this trial is testing

Study of IK-595 in RAS- or RAF-altered Advanced Tumors

Who this might be right for
Solid Tumor, AdultColorectal CancerPancreatic Cancer+7 more
Ikena Oncology 75
Large-scale testing (Phase 3)Study completedNCT01689519
What this trial is testing

A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma

Who this might be right for
Malignant Melanoma
Hoffmann-La Roche 495
Early research (Phase 1)Looking for participantsNCT06326411
What this trial is testing

Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

Who this might be right for
OncologyMEK MutationRAF Gene Mutation+6 more
Nested Therapeutics, Inc 230
Testing effectiveness (Phase 2)Study completedNCT06208124
What this trial is testing

IMM-6-415 in RAS/RAF Mutant Solid Tumors

Who this might be right for
Advanced Solid Tumor (Phase 1)Pancreas AdenocarcinomaNon-small Cell Lung Cancer+1 more
Immuneering Corporation 30
Large-scale testing (Phase 3)Active Not RecruitingNCT04940052
What this trial is testing

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

Who this might be right for
Differentiated Thyroid Cancer (DTC)
Novartis Pharmaceuticals 153
Next Page